Consistent with these data, low circulating levels of SIRT4 were found in obese patients with NAFLD and early atherosclerosis, likely mirroring its reduced mitochondrial expression in an attempt to increase fat oxidative capacity and mitochondrial function in the liver and muscle [148]. Here, SIRT4 is linked to metabolic dysfunction-associated steatotic liver disease.